Scientific Advisory Board
Andrea Amalfitano, D.O. Ph.D.
Chairman of Scientific Advisory Board
Dr. Andrea Amalfitano is Chairman of Etubics’ Scientific Advisory Board. A pioneering gene therapist, Dr. Amalfitano received both his PhD and medical degree from Michigan State University and performed his residency at the Mayo Clinic. While at the University of Michigan he was instrumental in creating the Etubics Platform. Dr. Amalfitano continued his gene therapy research as a professor at Duke University Medical Center. He is presently at Michigan State University where he was appointed the Osteopathic Heritage Foundation Endowed Chairperson. Dr. Amalfitano continues his work using adenoviral vectors for vaccine development and gene therapy.
John H. Lee, MD
John Lee grew up on a small dairy farm in Northern Minnesota. He did his undergraduate education at Stanford University graduating with honors in biology. He completed his medical school at University of Minnesota. Residency and fellowship were performed in Head and Neck Surgery at the University of Iowa. He stayed on staff and was promoted to associate professor. During time from undergraduate throughout his career he has focused not only on medical training but also translational research. In 2008 he took a position to build a head and neck cancer program at Sanford Health. While there as the physician lead for the system he developed a large head and neck program that focuses on bringing immune oncology drugs to patients. Academically, he was promoted to full professor and also was promoted to medical director of oncology research. He initiated and chairs the systems protocol review committee for all incoming oncology trials and has developed several initiated trials within Sanford. His passion is to improve long term cures and reduce morbidity of oncology treatments using the bodies’ immune response. In addition his lab has produced over 40 peer-reviewed papers, multiple patents and maintained continuous NIH funding. For enjoyment he enjoys the outdoors , especially hunting and fishing.
Slobodan Paessler, D.V.M., Ph.D.
Dr. Paessler is currently a Professor in the Department of Pathology and Director of Galveston National Laboratory Preclinical Studies Core. He also serves as the Director of Animal Biosafety Level 3 for the Institute of Human Infections and Immunity and is a member of the Center for Biodefense & Emerging Infectious Diseases. He received a Dr. Med Vet (D.V.M) at Ludwig-Maximalian University and a Ph.D in Experimental Pathology from UTMB. The research in his laboratory has focused on viral pathogenesis, vaccine development and on development of animal models to test new vaccine candidates and antiviral drugs. Dr. Paessler is a co-principle investigator on the Company’s Universal Influenza Vaccine project funded by an NIAID grant.
A. Dusty Miller, Ph.D.
Dr. A. Dusty Miller is a member of the Company’s Scientific Board of Advisors and a Consultant to the Company. He is an early pioneer in gene therapy research. Dr. Miller is an Advising Member of the Fred Hutchinson Cancer Research Center and an Affiliate Professor of Pathology at the University of Washington, both in Seattle, where he has focused on the development of viral vectors derived from retroviruses and adeno-associated viruses and has demonstrated gene transfer and expression in many somatic cell types in culture and in animals. He received his Ph.D. in Pharmacology from Stanford University and completed a post-doctoral fellowship with Dr. Inder Verma at the Salk Institute. In 1999, the National Hemophilia Foundation named him Researcher of the Year and in 2002 Dr. Miller was named an ISI Highly Cited Researcher. Dr. Miller is a founding member of the American Society for Gene Therapy.